Literature DB >> 8423198

Transient cisplatin-resistant murine fibrosarcoma cell characterized by increased metallothionein content.

H Eichholtz-Wirth1, R Born, G Reidel, B Hietel.   

Abstract

Cisplatin-resistant mouse fibrosarcoma cells, SSK-R, were isolated after short and low-dose drug treatment of the sensitive SSK cells in vitro. These SSK-R sublines exhibit up to sevenfold cisplatin resistance and are characterized mainly by an increased metallothionein content. Loss of drug resistance after about 140-180 cell divisions in drug-free medium coincides with loss of metallothionein content. The glutathione level is the same in the sensitive and resistant sublines; inhibition of glutathione synthesis by buthionine sulphoximine enhances the sensitivity in both cells lines by a factor of 2.7. The resistant sublines are not cross-resistant to radiation; a radiation exposure followed immediately by cisplatin treatment results in an additive effect. The cellular cisplatin content is slightly reduced in SSK-R2 cells and it remains at this level also upon loss of drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423198     DOI: 10.1007/bf01624435

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  26 in total

1.  Interactions between antitumor drugs and radiation in mammalian tumor cell lines: differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposure in vitro.

Authors:  B T Hill; R D Whelan; L K Hosking; S A Shellard; P Bedford; R B Lock
Journal:  NCI Monogr       Date:  1988

2.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

3.  Increased resistance to chlorambucil in cultured cells with a high concentration of cytoplasmic metallothionein.

Authors:  L Endresen; A Bakka; H E Rugstad
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

4.  Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells.

Authors:  W R Waud
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

5.  Effect of cisplatin resistance on cellular radiation response.

Authors:  K E Wallner; G C Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-04       Impact factor: 7.038

6.  Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents.

Authors:  B Kaina; H Lohrer; M Karin; P Herrlich
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

7.  Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.

Authors:  R J Schilder; L Hall; A Monks; L M Handel; A J Fornace; R F Ozols; A T Fojo; T C Hamilton
Journal:  Int J Cancer       Date:  1990-03-15       Impact factor: 7.396

8.  Cisplatin and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastases.

Authors:  J M Onoda; J R Jacobs; J D Taylor; B F Sloane; K V Honn
Journal:  Cancer Lett       Date:  1986-02       Impact factor: 8.679

9.  X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines.

Authors:  J L Schwartz; J Rotmensch; M A Beckett; D R Jaffe; M Toohill; S M Giovanazzi; J McIntosh; R R Weichselbaum
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

10.  The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line.

Authors:  C Meijer; N H Mulder; G A Hospers; D R Uges; E G de Vries
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more
  1 in total

1.  Radiation-induced transient cisplatin resistance in murine fibrosarcoma cells associated with elevated metallothionein content.

Authors:  H Eichholtz-Wirth; G Reidel; B Hietel
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.